Literature DB >> 25638540

Expanded access programmes: patient interests versus clinical trial integrity.

Paul Lorigan1, Paolo A Ascierto2, Reinhard Dummer3, Alexander M Eggermont4, Keith T Flaherty5, Claus Garbe6, Helen Gogas7, Axel Hauschild8, Richard F Kefford9, John M Kirkwood10, James Larkin11, Georgina V Long12, Michele Maio13, Grant A McArthur14, Antoni Ribas15, Caroline Robert16, Dirk Schadendorf17, Vernon K Sondak18, Jedd D Wolchok19, Andrew M Hudson20.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25638540     DOI： 10.1016/S1470-2045(14)71161-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  Oncologists' reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center.

Authors:  Jeremiah Stout; Cambray Smith; Jan Buckner; Alex A Adjei; Mark Wentworth; Jon C Tilburt; Zubin Master
Journal:  PLoS One       Date:  2021-12-17       Impact factor: 3.240

2.  Going "social" to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access.

Authors:  Tim K Mackey; Virginia J Schoenfeld
Journal:  BMC Med       Date:  2016-02-02       Impact factor: 8.775

3.  Ethics framework for treatment use of investigational drugs.

Authors:  Jan Borysowski; Andrzej Górski
Journal:  BMC Med Ethics       Date:  2020-11-18       Impact factor: 2.652
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.